ZHIFEI-BIOL(SZ:300122) Jin Rong Jie·2025-08-13 01:45Core Viewpoint - The launch of the quadrivalent influenza vaccine by Zhifei Biological's subsidiary marks a significant breakthrough in the influenza vaccine sector, enhancing the company's capabilities in infectious disease prevention [1][3]. Group 1: Vaccine Launch and Market Impact - The quadrivalent influenza vaccine has been developed to address the seasonal flu, which causes 3 to 5 million severe cases and 290,000 to 650,000 respiratory disease-related deaths globally each year [3]. - The vaccine is designed for individuals aged 3 and above and is produced using WHO-recommended influenza virus strains, ensuring good safety profiles [5][7]. - The introduction of this vaccine increases the availability of preventive options for the public, particularly benefiting high-risk groups such as infants, the elderly, pregnant women, and chronic disease patients [3][5]. Group 2: Research and Development Pipeline - The company has multiple influenza vaccine products in the pipeline, including a quadrivalent influenza vaccine for children and a trivalent influenza vaccine, both of which are in the application review stage for market approval [7]. - Other products under development include a quadrivalent influenza vaccine with adjuvant, currently in Phase I and II clinical trials, and a trivalent influenza vaccine with adjuvant that has received clinical approval [7][10]. - The company is also advancing various other vaccine candidates, including a freeze-dried rabies vaccine, a 15-valent pneumococcal conjugate vaccine, and a quadrivalent recombinant norovirus vaccine, among others [10][12]. Group 3: Strategic Vision and Future Plans - Zhifei Biological aims to enhance its independent innovation capabilities across various fields, including vaccines and bioproducts, while establishing a comprehensive "prevention & treatment" industry layout [12]. - The company is committed to addressing public health needs and aligning its product strategy with market demands and industry trends to contribute to global epidemic prevention efforts [12].